Skip to main content

Table 2 Patient characteristics in the NORDIC-VII study

From: Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

 

LCS6 wild-type (N=451)

LCS6 variant (N=84)

Arm

A

B

C

A

B

C

N

154

148

149

26

33

25

%

86

82

86

14

18

14

Age, years

Median

60.4

60.8

63.7

63.8

60.6

62.3

Min

29.9

24.1

33.1

37.1

38.0

36.3

Max

74.8

74.4

74.9

74.7

73.7

74.0

Sex (%)

Male

56

63

60

46

70

76

Female

44

37

40

54

30

24

Location primary tumor (%)

Colon

55

53

66

65

61

52

Rectum

45

47

34

35

39

48

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us